CD274 and neoplasm: A phase II clinical study of Olaparib and Durvalumab in the combination therapy for recurrent ovarian cancer has demonstrated that the combination of PARPi and anti-PD-L1 creates an immune stimulatory environment that can enhance durable anti-tumor immune response in the BRCA wild-type population toward immune checkpoint blockade (201).